Devyser launches a new updated NGS assay to simplify thalassemia testing
Devyser has launched Devyser Thalassemia v2, a next-generation sequencing (NGS) solution designed...
What if thalassemia testing was simple and rapid?
Devyser Thalassemia v2 is a rapid next-generation sequencing (NGS) solution tailored for comprehensive genetic testing of alpha and beta thalassemia. This assay delivers robust detection of all relevant alpha and beta thalassemia variants in the HBA1/2, HBB, HBD, and HBG1/2 genes, along with CNVs, complex variants, and additional beta modifiers. With minimal hands-on time and a streamlined workflow, Devyser Thalassemia v2 enables fast, reliable results, making it ideal for research laboratories worldwide.
Devyser Thalassemia v2 – Product features
A simple NGS solution for comprehensive genetic testing of alpha and beta thalassemia, including beta modifiers with robust CNV detection.
Achieve same-day library preparation with a streamlined workflow requiring minimal hands-on time. Designed for high-throughput results, this solution enhances operational efficiency and significantly reduces turnaround times for your lab.
Efficient genetic profiling
This system comprehensively covers the globin gene clusters, capturing all relevant alpha and beta thalassemia variants. Its robust detection capabilities accurately identify even the most complex genetic mutations.
User-friendly software reduces the need for bioinformatics expertise, allowing for efficient, reliable variant analysis. Its scalability allows labs to easily handle growing workloads, offering batch export options for streamlined data management.
What differentiates Devyser Thalassemia v2?
Comprehensive variant detection
Devyser Thalassemia v2 identifies various genetic variations, including SNVs, indels, and complex CNVs. It detects mutations in a broad target region, covering multiple areas of the globin gene clusters, including key beta-modifiers.
Enhanced CNV detection
This solution can detect challenging alpha thalassemia deletions such as α3.7 and α4.2 through integrated long-range PCR, reducing the need for reruns.
Why choose Devyser Thalassemia v2?
Devyser Thalassemia v2 reduces the complexity of genetic testing for thalassemia by combining multiple detection methods into a single assay. This rapid NGS solution requires minimal hands-on time. It covers all relevant alpha and beta thalassemia variants in the HBA1/2, HBB, HBD, and HBG1/2 genes, along with CNVs, complex variants, and additional beta modifiers. Devyser Thalassemia v2 includes new direct detections to tackle challenging alpha thalassemia deletions, such as α3.7 and α4.2. The dedicated software allows intuitive and efficient variant analysis, making Devyser Thalassemia v2 an ideal choice for reliable, comprehensive genetic profiling in the lab.
Contact us to discover how Devyser Thalassemia v2 can streamline your lab workflow.
Instructions for use
Enter access code found in the lower right corner of the label on the kit box.
Certificates
Download a specific Batch Release Certificate (BRC) below.
Guidelines and handbooks (1)
Product information (0)
Software settings (4)
Safety data sheets (1)
Data tables (0)
Enter access code found in the lower right corner of the label on the kit box.
Download a specific Batch Release Certificate (BRC) below.
RUO
Devyser Thalassemia v2
A simple NGS solution for comprehensive genetic testing of alpha and beta thalassemia, including beta modifiers with robust CNV detection.
8-A414-24-RUO
Pack size: 24
How is Devyser Thalassemia v2 different than Devyser Thalassemia?
Devyser Thalassemia v2 expands on the robust CNV detection by introducing a direct detection for two common deletions: α3.7 and α4.2 deletions. It also includes key beta modifiers that may influence the levels of hemoglobin.
How can you detect CNVs in homologous HBA regions?
By introducing a long-range PCR, the homologous HBA region is covered in one single amplification.
What technology is used for this assay?
How long is the laboratory workflow?
Devyser has launched Devyser Thalassemia v2, a next-generation sequencing (NGS) solution designed...
Read More
Thalassemia and hemoglobinopathies are among the most common genetic disorders worldwide, affecting...
Read More
Read More
Read More